Carmell Price To Book Ratio from 2010 to 2024

CTCXW Stock   0.06  0  1.96%   
Carmell Therapeutics Price To Book Ratio yearly trend continues to be fairly stable with very little volatility. Price To Book Ratio is likely to outpace its year average in 2024. Price To Book Ratio is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. View All Fundamentals
 
Price To Book Ratio  
First Reported
2010-12-31
Previous Quarter
1.69665963
Current Value
1.78
Quarterly Volatility
2.85839688
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Carmell Therapeutics' Price To Book Ratio Growth Pattern

Below is the plot of the Price To Book Ratio of Carmell Therapeutics over the last few years. It is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. Carmell Therapeutics' Price To Book Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price To Book Ratio10 Years Trend
Slightly volatile
   Price To Book Ratio   
       Timeline  

Carmell Price To Book Ratio Regression Statistics

Arithmetic Mean(5.26)
Coefficient Of Variation(54.36)
Mean Deviation1.87
Median(6.43)
Standard Deviation2.86
Sample Variance8.17
Range8.2099
R-Value0.63
Mean Square Error5.33
R-Squared0.39
Significance0.01
Slope0.40
Total Sum of Squares114.39

Carmell Price To Book Ratio History

2024 1.78
2023 1.7
2022 -5.19

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Price To Book Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Book Ratio 1.70  1.78 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.